Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Dose-dense therapy or every-3-week therapy can now be used in several additional combinations in the primary therapy setting. A variety of combinations and strategies are being attempted, which can be difficult to do with intraperitoneal (IP) chemotherapy, explains Sabbatini.

IP chemotherapy is traditionally used to treat patients with ovarian cancer and can treat other gynecologic malignancies, except endometrial or cervical cancers, says Sabbatini.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Ovarian Cancer

GSK-22-OSD1278 - /clinical/ovarian-cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Sabbatini on the Future of Dose-Dense Therapy in Ovarian Cancer